HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a Buy rating on Zevra Therapeutics (NASDAQ:ZVRA) and maintained a $15 price target.
March 05, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Oren Livnat reiterates a Buy rating on Zevra Therapeutics with a $15 price target.
The reiteration of a Buy rating and a maintained price target of $15 by a reputable analyst suggests a positive outlook for Zevra Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100